LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
ROIV
Roivant Sciences Ltd.
There isn't enough reported data to score ROIV yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ROIV Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Under pressure | |
| Strong |
ROIV's revenue and balance sheet are currently strong, but its profitability and cash flow are under pressure.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ROIV PE Valuation
ROIV has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ROIV Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect ROIV's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ROIV on earnings quality, reporting a profit while its opponent remains loss making.
ROIV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.57 | -$0.02 |
| Q2 2026 | -$0.47 | +$0.22 |
| Q1 2026 | -$0.54 | -$0.30 |
| Q4 2025 | -$1.16 | -$1.02 |
| Q3 2025 | -$0.55 | -110% |
| Q2 2025 | -$0.69 | -112% |
| Q1 2025 | -$0.24 | -105% |
| Q4 2024 | -$0.14 | -103% |
ROIV is still losing money, but far less than before: $0.57 per share over the past year, against $1.55 at its worst in late 2022.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ROIV on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over ROIV on profitability, with a higher operating margin.
ROIV Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $35.1M | +2136% |
| Q2 2026 | $1.4M | -34% |
| Q1 2026 | $2.5M | -67% |
| Q4 2025 | $2M | -78% |
| Q3 2025 | $1.6M | -65% |
| Q2 2025 | $2.2M | -96% |
| Q1 2025 | $7.6M | -74% |
| Q4 2024 | $9M | -76% |
ROIV's revenue is recovering but still below its 2024 peak: $35M last quarter, up 2136% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -763% | +18730 points |
| Q2 2026 | -25381% | -12251 points |
| Q1 2026 | 16478% | +20242 points |
| Q4 2025 | -16966% | -13924 points |
| Q3 2025 | -19493% | -11857 points |
| Q2 2025 | -13130% | -12912 points |
| Q1 2025 | -3764% | -2845 points |
| Q4 2024 | -3043% | -16669 points |
ROIV's operating margin was −763% last quarter, up 18730 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over ROIV on cash generation, producing positive trailing cash flow while its opponent burns cash.
ROIV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $594.2M | +$787.7M |
| Q2 2026 | -$270.9M | -$62.5M |
| Q1 2026 | -$165.1M | +$8.3M |
| Q4 2025 | -$191.5M | +$17.5M |
| Q3 2025 | -$193.5M | +$74.3M |
| Q2 2025 | -$208.4M | -$14.6M |
| Q1 2025 | -$173.4M | -$64.6M |
| Q4 2024 | -$209.1M | +$1.7M |
ROIV has burned cash in almost every quarter: −$33M over the past year, against −$784M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ROIV on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ROIV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +2M shares |
| 1 year | +6.1% | +41.8M shares |
| 3 years | -6.2% | -47.5M shares |
| 5 years | +11% | +72.5M shares |
ROIV has 723M diluted shares, up 6.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $74.5M |
| Q2 2026 | $206.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $208.3M |
| Q1 2025 | $295.4M |
| Q4 2024 | $243.3M |
| Q3 2024 | $106.1M |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ROIV Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2024 | -0.5x | Net Cash |
| Q2 2024 | -1.2x | Net Cash |
| Q1 2024 | -1.4x | Net Cash |
| Q4 2023 | -1.5x | Net Cash |
ROIV has more cash than debt.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ROIV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.8 | Neutral |
| Stochastic | 60.6 | Neutral |
ROIV's weekly RSI is 65 (neutral) and its Stochastic is 61 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ROIV PE vs Healthcare Sector
| Metric | ROIV | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ROIV has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
ROIV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $36.6 | 9.3% above |
| 20 week MA | $36.3 | 10% above |
| 50 week MA | $30.6 | 31% above |
| 100 week MA | $21.6 | 85% above |
| 200 week MA | $16.0 | 149% above |
ROIV is in an uptrend: it's above all five of its weekly moving averages, and 149% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.
ROIV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.92 | $10.1 | +1.8% |
| 2021 | $10.1 | $12.0 | +18% |
| 2022 | $12.0 | $7.01 | -41% |
| 2023 | $7.01 | $11.2 | +60% |
| 2024 | $11.2 | $11.8 | +5.1% |
| 2025 | $11.8 | $22.2 | +88% |
| 2026 YTD | $22.2 | $40.0 | +80% |
ROIV has the edge over LLY on returns for 2026, with the stronger performance.